AKT1-IN-13 是一种口服有效的 AKT1 抑制剂(IC50 为 5.17 μM),对 PAK1、PKA、MAP2K1 (MEK1 / MAPKK1) 和 MAPK1 (ERK2) 也具有高抑制活性,可通过诱导细胞凋亡 (apoptosis)、激活促凋亡蛋白 BAX、抑制抗凋亡蛋白 Bcl-2 并激活 caspase 3 发挥作用,作为一种细胞毒性试剂以 AKT1 依赖的方式对原位移植肝癌发挥杀伤作用,可用于肝细胞癌的相关研究。
AKT1-IN-13
产品编号: MS-T10954 分子式: C43H45BrN4O6 分子量: 793.74
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

AKT1-IN-13 是一种口服有效的 AKT1 抑制剂(IC50 为 5.17 μM),对 PAK1、PKA、MAP2K1 (MEK1 / MAPKK1) 和 MAPK1 (ERK2) 也具有高抑制活性,可通过诱导细胞凋亡 (apoptosis)、激活促凋亡蛋白 BAX、抑制抗凋亡蛋白 Bcl-2 并激活 caspase 3 发挥作用,作为一种细胞毒性试剂以 AKT1 依赖的方式对原位移植肝癌发挥杀伤作用,可用于肝细胞癌的相关研究。

生物实验数据

生物活性 AKT1-IN-13 is an orally active AKT1 inhibitor with an IC50 of 5.17 μM that also exhibits high inhibitory activity against PAK1, PKA, MAP2K1 (MEK1 / MAPKK1), and MAPK1 (ERK2), induces apoptosis, activates the pro-apoptotic protein BAX, inhibits the anti-apoptotic protein Bcl-2, and activates caspase 3, and, as a cytotoxic agent, exerts killing effects on orthotopically transplanted liver cancer in an AKT1-dependent manner, making it useful for research related to hepatocellular carcinoma.
IC50 & Target

Akt1

5.17 μM (IC50)

PAK1

 

MEK1

 

ERK2

 

Bax

 

Bcl-2

 

Caspase 3

 

体外研究
(In Vitro)

AKT1-IN-13 (Compound 17) (1.0 μM; 50 min) 是一种多靶点激酶抑制剂,可强效抑制 AKT1 (1 μM 时抑制率达 95%),并在 1 μM 时对另外 4 种激酶 (PAK1、PKA、MAP2K1、MAPK1) 的抑制率均 > 80%。
AKT1-IN-13 (72 h) 可强效抑制人肝癌 HepG2 细胞的增殖,其 IC50 为 2.09 μM,选择指数高达 11.53。
AKT1-IN-13 (2-6 μM; 48 h) 可呈浓度依赖性诱导人肝癌 HepG2 细胞发生凋亡。
AKT1-IN-13(2-6 μM; 48 h) 可呈浓度依赖性抑制人肝癌 HepG2 细胞的迁移。
AKT1-IN-13 (2-6 μM; 24 h) 以浓度依赖的方式抑制人肝癌 HepG2 细胞的侵袭。
AKT1-IN-13 (2-6 μM; 48 h) 可在体外以浓度依赖的方式降低人肝癌 HepG2 细胞的线粒体跨膜电位。
AKT1-IN-13 (2-6 μM; 48 h) 可在体外以浓度依赖的方式诱导人肝癌 HepG2 细胞发生 G0/G1 期细胞周期阻滞。
AKT1-IN-13 (2-6 μM; 48 h) 可在体外以浓度依赖的方式抑制人肝癌 HepG2 细胞中 AKT 的磷酸化并激活凋亡通路,降低 p-AKT 水平同时上调促凋亡蛋白的表达。

Apoptosis Analysis

Cell Line: human liver cancer HepG2 cells
Concentration: 2, 4 and 6 μM
Incubation Time: 48 h
Result: Induced a concentration-dependent increase in apoptosis rates: early apoptosis rates rose from 2.42% (control) to 19.49% at 6 μM.
Caused morphological changes including loss of cell membrane smoothness and smaller nuclei.

Cell Migration Assay

Cell Line: human liver cancer HepG2 cells
Concentration: 2, 4 and 6 μM
Incubation Time: 48 h
Result: Inhibited HepG2 cell migration in a concentration-dependent manner, reducing the wound healing rate from 36.49% (control) to 3.43% at 6 μM.

Cell Invasion Assay

Cell Line: human liver cancer HepG2 cells
Concentration: 2, 4 and 6 μM
Incubation Time: 24 h
Result: Inhibited HepG2 cell invasion in a concentration-dependent manner, reducing the percentage of invasive cells from 100% (control) to 19.85% at 6 μM.

Cell Cycle Analysis

Cell Line: human liver cancer HepG2 cells
Concentration: 2, 4 and 6 μM
Incubation Time: 48 h
Result: Induced concentration-dependent G0/G1 phase arrest: the percentage of cells in G0/G1 phase increased from 65.30% (control) to 79.77% at 6 μM.
Decreased S phase percentage from 24.03% to 13.62% and G2/M phase percentage from 10.67% to 6.61%.

Western Blot Analysis

Cell Line: human liver cancer HepG2 cells
Concentration: 2, 4 and 6 μM
Incubation Time: 48 h
Result: Reduced p-AKT (Ser473) levels in a concentration-dependent manner (P < 0.01) while total AKT levels remained unchanged.
Decreased Bcl-2 expression, increased BAX expression, and elevated cleaved-caspase-3 and cleaved-PARP levels in a concentration-dependent manner.
体内研究
(In Vivo)

AKT1-IN-13 (Compound 17) (50-100 mg/kg;灌胃;每日一次;连续 14 天) 可通过 AKT1 依赖的机制强效抑制雄性 C57BL/6 小鼠的原位肝细胞癌生长,使平均肿瘤重量降低 56% 以上,同时维持良好的安全性,对小鼠体重无影响。

Animal Model: C57BL/6 (male, 3-4 weeks old, 16-18 g, orthotopic liver cancer transplantation model via Hepa1-6 cancer tissue implantation)
Dosage: 50 mg/kg; 100 mg/kg
Administration: i.g.; daily; 14 days
Result: Reduced average tumor weight to 0.90 g (50 mg/kg group) and 0.86 g (100 mg/kg group) compared to 2.09 g in vehicle control group.
Reduced HCC cell infiltration, disordered arrangement, and multinuclear cell levels in treated groups relative to controls.
Reduced p-AKT levels significantly in both treatment groups compared to controls, with no significant change in total AKT protein levels.
Caused no significant changes in mouse body weight during the study period.

化学信息

分子量 793.74
分子式 C43H45BrN4O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础